Press Release

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine's REAL Space, the world’s largest source of make-on-demand small molecules. Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized compounds designed to accelerate drug discovery against the hundred most difficult to address biological areas and clinically relevant key drug targets.

Enamine, the leading provider of chemical compounds and drug discovery services, and ChemPass, a contract research organization for computational and AI-assisted software, today announced their start of strategic partnership to provide hit discovery solutions to their customers.

Enamine, Chemspace, and PharmAI Discovery GmbH (PAID) start a transformative collaboration to accelerate the advancement of theranostics through AI-driven drug discovery with emphasis on cancer diagnosis and therapy. This collaboration brings together the success of Enamine’s discovery biology and chemistry competencies, Chemspace’s expertise in ultra-large chemical space exploration for drug discovery, and PAID’s AI-powered molecular discovery platform to identify and develop promising drug candidates faster and with greater precision, both for conventional and molecular radiotherapy and radio diagnostics.

Elsevier, a global leader in information and analytics, and Enamine, a global leader in supplying small molecules and early drug discovery services, have announced a partnership to integrate Enamine's database of over 43 million make-on-demand (MADE) analog compounds into Reaxys. The integration will provide chemists with unparalleled access to a diverse array of chemical compounds for accelerated drug discovery and materials science research.

Enamine, a scientifically driven provider of chemistry and biology services with the world’s largest catalog of building blocks screening compounds, announced today performance results for Enamine Fast MADE building blocks.

Chemspace, an expert in the generation and exploration of ultra-large chemical datasets, and Enamine, a global leader in supplying small molecules and early drug discovery services, are pleased to announce an expansion of their collaboration to improve delivery times of molecules from Chemspace Freedom Space.

Chemspace, an expert in the generation and exploration of ultra-large chemical datasets, and Enamine, a global leader in supplying small molecules and early drug discovery services, are excited to announce a collaboration to unveil the real potential of Enamine’s chemistry capabilities and deliver unparalleled discovery solutions. By combining their unique strengths, both companies aim to accelerate and enhance the process of identifying and developing new active molecules.

FarmHannong, a leading company in the Korean agricultural industry, and Enamine Ltd, the world’s premier provider of chemical building blocks, screening compounds, and integrated discovery chemistry services, have announced the start of their collaboration.

Syntekabio collaborates with global compound supplier Enamine on AI-driven synthetic drug development and global market expansion through a strategic partnership.

K-MEDI hub (Daegu-Gyeongbuk Medical Innovation Foundation, Chairman Jin-Young Yang) announced on the 29th that it has signed a Memorandum of Understanding (MOU) with Enamine to develop the K-DEL platform technology and establish a collaborative research framework for drug development.

Burlingame, CA (USA), Kyiv (Ukraine) – August 16th, 2024 — Collaborative Drug Discovery (CDD), a leader in providing scientific informatics solutions, announced today that its flagship platform, CDD Vault, now includes the complete compound collection of Enamine, a leading provider of chemical compounds and early discovery services, within its AI module for structural similarity searches. This integration enhances the platform's capabilities, offering users an unprecedented breadth of chemical diversity and precision in their research endeavors.

Hamburg, Germany, and Kyiv, Ukraine — August 14th, 2024 — iniuva GmbH, a Hamburg-based pioneering biotech startup specializing in AI-powered drug discovery, and Enamine Ltd, a Kyiv-based leading provider of chemical compounds and related services, today announced a collaborative research and development program.

Cresset, an in silico solutions provider for drug discovery, has extended its collaboration with Enamine.

Cresset and the chemical and biological CRO are looking to develop targeted protein degraders (TPDs), which can be used to develop therapeutic interventions for a number of diseases.

We are pleased to announce the release of a new product from Enamine – Compound Tuning Kits that help you adjust properties of the developed molecules. Today, we introduce Basicity-Tuning Kits of amines as the most common building blocks of drugs playing a significant role in numerous biological systems.

Tokyo, Japan, and Kyiv, Ukraine, 21 June 2024. SyntheticGestalt, an AI company specializing in the life sciences domain, and Enamine, a pioneer in the creation of ultra-large chemical spaces of highly feasible compounds, announced today a new research program involving the application of AI for novel drug discovery, followed by biological tests of REAL compounds directly at Enamine (B-REAL).

Barcelona, Spain, and Kyiv, Ukraine, 7 May 2024. Pharmacelera, the leading provider of computational tools for hit discovery, and Enamine, the developer of the world’s largest and most reputable virtual space: REAL, have announced the extension of their current partnership to explore an extraordinary magnitude of compounds, that has been extended by a 10 fold factor – when compared to the early version. Ultra-large chemical libraries constitute a key paradigm to tap into new and still unexplored chemical spaces, increasing the probability for the researcher to find new and chemically diverse potent hits for Discovery Programs. Efficient handling of the ultra-large compound libraries still remains the main challenge.

Kemptthal, Switzerland and Kyiv, Ukraine, April 29, 2024: Synple Chem, an innovative developer of integrated automated chemical synthesis solutions, announced today a strategic partnership with Enamine, a world-renowned supplier of building blocks. The partners agreed to jointly develop a new chemical space by fueling the world’s largest collection of building blocks provided by Enamine to Synple Chem’s reaction outcome prediction tools. Researchers will be able to download the resulting compound library and search it using their workflows. Selected compounds will be synthesized by Synple Chem’s automated synthesis platform.

Cambridge, UK and Kyiv, Ukraine, 11 April 2024: Metrion Biosciences Limited (“Metrion”), the specialist ion channel and cardiac safety screening contract research organisation (CRO) and drug discovery company, and Enamine Ltd (“Enamine”), the global leader in supplying small molecules and early drug discovery services, announced that Metrion has enhanced its High Throughput Screening (HTS) services with the addition of access to Enamine’s compound libraries.

March, 2024, Kyiv, Ukraine. Enamine Ltd, the global leader in supplying small molecules and early drug discovery services, announces the expansion of its library synthesis capabilities with a focus on Enamine REAL compounds to further support the growing demands of agricultural and pharmaceutical companies, research institutes, and drug discovery centers.

Cresset recently announced a collaboration with Enamine, the world’s leading provider of chemical building blocks and drug discovery services to develop innovative new solutions for the early drug discovery process.